Cargando…
Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
SIMPLE SUMMARY: Despite the implementation of efficient screening and vaccination programs, uterine cervical cancer remains a leading cause of cancer-related mortality in women worldwide. New therapeutic approaches have so far failed to improve treatment response and prognosis significantly, especia...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616420/ https://www.ncbi.nlm.nih.gov/pubmed/34830902 http://dx.doi.org/10.3390/cancers13225748 |
_version_ | 1784604343998087168 |
---|---|
author | Fleischmann, Maximilian Chatzikonstantinou, Georgios Fokas, Emmanouil Wichmann, Jörn Christiansen, Hans Strebhardt, Klaus Rödel, Claus Tselis, Nikolaos Rödel, Franz |
author_facet | Fleischmann, Maximilian Chatzikonstantinou, Georgios Fokas, Emmanouil Wichmann, Jörn Christiansen, Hans Strebhardt, Klaus Rödel, Claus Tselis, Nikolaos Rödel, Franz |
author_sort | Fleischmann, Maximilian |
collection | PubMed |
description | SIMPLE SUMMARY: Despite the implementation of efficient screening and vaccination programs, uterine cervical cancer remains a leading cause of cancer-related mortality in women worldwide. New therapeutic approaches have so far failed to improve treatment response and prognosis significantly, especially in patients with recurrent disease or metastases. Further, robust molecular markers to predict therapy response and survival are scarce and their routine use is limited in clinical practice. Accordingly, there is an urgent need to identify and establish molecular markers to predict therapy response and clinical outcome to improve treatment and survival in cervical cancer. ABSTRACT: Uterine cervical cancer is one of the leading causes of cancer-related mortality in women worldwide. Each year, over half a million new cases are estimated, resulting in more than 300,000 deaths. While less-invasive, fertility-preserving surgical procedures can be offered to women in early stages, treatment for locally advanced disease may include radical hysterectomy, primary chemoradiotherapy (CRT) or a combination of these modalities. Concurrent platinum-based chemoradiotherapy regimens remain the first-line treatments for locally advanced cervical cancer. Despite achievements such as the introduction of angiogenesis inhibitors, and more recently immunotherapies, the overall survival of women with persistent, recurrent or metastatic disease has not been extended significantly in the last decades. Furthermore, a broad spectrum of molecular markers to predict therapy response and survival and to identify patients with high- and low-risk constellations is missing. Implementation of these markers, however, may help to further improve treatment and to develop new targeted therapies. This review aims to provide comprehensive insights into the complex mechanisms of cervical cancer pathogenesis within the context of molecular markers for predicting treatment response and prognosis. |
format | Online Article Text |
id | pubmed-8616420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86164202021-11-26 Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer Fleischmann, Maximilian Chatzikonstantinou, Georgios Fokas, Emmanouil Wichmann, Jörn Christiansen, Hans Strebhardt, Klaus Rödel, Claus Tselis, Nikolaos Rödel, Franz Cancers (Basel) Review SIMPLE SUMMARY: Despite the implementation of efficient screening and vaccination programs, uterine cervical cancer remains a leading cause of cancer-related mortality in women worldwide. New therapeutic approaches have so far failed to improve treatment response and prognosis significantly, especially in patients with recurrent disease or metastases. Further, robust molecular markers to predict therapy response and survival are scarce and their routine use is limited in clinical practice. Accordingly, there is an urgent need to identify and establish molecular markers to predict therapy response and clinical outcome to improve treatment and survival in cervical cancer. ABSTRACT: Uterine cervical cancer is one of the leading causes of cancer-related mortality in women worldwide. Each year, over half a million new cases are estimated, resulting in more than 300,000 deaths. While less-invasive, fertility-preserving surgical procedures can be offered to women in early stages, treatment for locally advanced disease may include radical hysterectomy, primary chemoradiotherapy (CRT) or a combination of these modalities. Concurrent platinum-based chemoradiotherapy regimens remain the first-line treatments for locally advanced cervical cancer. Despite achievements such as the introduction of angiogenesis inhibitors, and more recently immunotherapies, the overall survival of women with persistent, recurrent or metastatic disease has not been extended significantly in the last decades. Furthermore, a broad spectrum of molecular markers to predict therapy response and survival and to identify patients with high- and low-risk constellations is missing. Implementation of these markers, however, may help to further improve treatment and to develop new targeted therapies. This review aims to provide comprehensive insights into the complex mechanisms of cervical cancer pathogenesis within the context of molecular markers for predicting treatment response and prognosis. MDPI 2021-11-17 /pmc/articles/PMC8616420/ /pubmed/34830902 http://dx.doi.org/10.3390/cancers13225748 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Fleischmann, Maximilian Chatzikonstantinou, Georgios Fokas, Emmanouil Wichmann, Jörn Christiansen, Hans Strebhardt, Klaus Rödel, Claus Tselis, Nikolaos Rödel, Franz Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer |
title | Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer |
title_full | Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer |
title_fullStr | Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer |
title_full_unstemmed | Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer |
title_short | Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer |
title_sort | molecular markers to predict prognosis and treatment response in uterine cervical cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616420/ https://www.ncbi.nlm.nih.gov/pubmed/34830902 http://dx.doi.org/10.3390/cancers13225748 |
work_keys_str_mv | AT fleischmannmaximilian molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT chatzikonstantinougeorgios molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT fokasemmanouil molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT wichmannjorn molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT christiansenhans molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT strebhardtklaus molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT rodelclaus molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT tselisnikolaos molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer AT rodelfranz molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer |